We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

54 hedge funds and large institutions have $32.7M invested in Neos Therapeutics, Inc in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

8% more capital invested

Capital invested by funds: $30.4M → $32.7M (+$2.33M)

6% more funds holding

Funds holding: 5154 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $23K

Holders
54
Holders Change
+3
Holders Change %
+5.88%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
10
Reduced
15
Closed
5
Calls
Puts
$23K
Net Calls
-$23K
Net Calls Change
-$16K
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$7.34M +$535K +356,588 +8%
NCM
2
Nantahala Capital Management
Connecticut
$6.96M
SFM
3
Sphera Funds Management
Israel
$5.33M -$566K -377,534 -10%
Goldman Sachs
4
Goldman Sachs
New York
$3.87M +$204K +135,859 +6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.66M
Renaissance Technologies
6
Renaissance Technologies
New York
$1.01M +$388K +258,706 +63%
Russell Investments Group
7
Russell Investments Group
United Kingdom
$874K +$871K +580,391 New
BlackRock
8
BlackRock
New York
$794K -$471 -314 -0.1%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$546K
DM
10
Deerfield Management
New York
$485K
Boston Partners
11
Boston Partners
Massachusetts
$347K +$344K +229,485 New
BCM
12
Bridgeway Capital Management
Texas
$317K
PCM
13
Proxima Capital Management
New York
$257K -$53.6K -35,706 -17%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$184K +$183K +121,752 New
BGIM
15
Brandywine Global Investment Management
Pennsylvania
$178K +$41.2K +27,495 +29%
Northern Trust
16
Northern Trust
Illinois
$151K -$10.1K -6,723 -6%
HAIM
17
Hunter Associates Investment Management
Pennsylvania
$151K +$150K +100,000 New
JP Morgan Chase
18
JP Morgan Chase
New York
$144K +$136K +90,696 +1,853%
OAM
19
Oxford Asset Management
United Kingdom
$136K -$97.3K -64,860 -42%
WA
20
Wealthstar Advisors
Texas
$111K
Wells Fargo
21
Wells Fargo
California
$101K +$2.8K +1,865 +3%
AIM
22
Alambic Investment Management
California
$78K -$17.6K -11,700 -18%
WG
23
Winton Group
United Kingdom
$76K -$58.1K -38,707 -43%
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$59K
AG
25
Algert Global
California
$52K -$57K -37,981 -53%

NEOS Hedge Fund Activity: Q4 2019 in Review

54 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2019, worth a combined $32.7M — up 7.7% from $30.4M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new NEOS positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 15 trimmed.

The largest buyer was Russell Investments Group, opening a new position worth an estimated $871K. The largest seller was Sphera Funds Management, cutting an estimated $566K.

  • 54 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2019, up from 51 in Q3 2019.
  • Funds reported $32.7M of Neos Therapeutics, Inc stock for Q4 2019, up 7.7% quarter-over-quarter.
  • 8 funds opened new Neos Therapeutics, Inc positions in Q4 2019 and 5 closed out, a net change of +3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q4 2019 was Russell Investments Group, an estimated $871K added.
  • The largest Neos Therapeutics, Inc seller in Q4 2019 was Sphera Funds Management, an estimated $566K sold.

Based on aggregated 13F filings for Q4 2019.